HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.2300
-0.0100 (-4.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2400
Open0.2495
Bid0.00 x 800
Ask0.00 x 800
Day's Range0.2300 - 0.2500
52 Week Range0.1500 - 0.5900
Volume270,620
Avg. Volume289,609
Market Cap11.25M
Beta (3Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.70
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before March 1, 2019, by which instructions to exercise subscription rights, along with the required subscription payment, must be received.

  • GlobeNewswire4 days ago

    Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today issued a reminder to stockholders that the record date of its proposed rights offering is Thursday, February 14, 2019. To be a stockholder of record on the record date, ownership of Hemispherx stock must occur by market close on Tuesday, February 12, 2019 to account for settlement. Under the proposed rights offering, Hemispherx will distribute to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date.

  • GlobeNewswire5 days ago

    Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical study supported by Merck that will combine the company’s Ampligen with Merck’s Keytruda for the treatment of recurrent, platinum-sensitive, ovarian cancer. The study will enroll up to 45 participants and be conducted at UPMC, which is sponsoring the study, by Robert Edwards, MD, director of the Ovarian Cancer Program at UPMC Magee Womens Hospital.

  • GlobeNewswire10 days ago

    Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

    A registration statement relating to the rights offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. The securities described below to be offered by exercising the rights distributed in the rights offering may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. If the SEC does not declare the registration statement effective by February 14, 2019, the rights offering will be delayed at least two months or may not proceed.

  • GlobeNewswire16 days ago

    Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference

    OCALA, Fla., Jan. 31, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc. CEO Tom Equels this week provided investors at NobleConXV with an update on the company’s ongoing.

  • GlobeNewswire20 days ago

    Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire23 days ago

    REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

    OCALA, Fla., Jan. 24, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs.

  • GlobeNewswire25 days ago

    Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

    OCALA, Fla., Jan. 23, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs.

  • GlobeNewswirelast month

    Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today Roswell Park Comprehensive Cancer Center Institutional Review Board (“IRB”) approval and shipment of Ampligen to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck’s Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer. The study will enroll at least six participants and be conducted by Drs. Mateusz Opyrchal and Pawel Kalinski at Roswell Park, a National Cancer Institute-designated comprehensive cancer center in Buffalo, New York.

  • GlobeNewswirelast month

    Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 325 recently manufactured vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Incline Village, Nevada, run by Daniel Peterson, MD. The vials will be used in the Expanded Access Program (“EAP”) known as “AMP-511”. The FDA authorized the AMP-511 protocol to treat ME/CFS patients in an effort to expand compassionate care in the fight against this quality-of-life impacting disease where there is no commercially approved therapy.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation

    Hemispherx Biopharma, Inc. (NYSE American:HEB) continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation and enable investors using the Apple device for their market information to find current and accurate HEB recent stories and news. Hemispherx announced on December 12, 2018, that it had learned that the Apple iOS12 Stocks Application (“App”), as a result of a recent update, has a “glitch” affecting a large number of public companies, including Hemispherx. The defect results in an erroneous news message which inaccurately informs certain iPhone and Apple portable device users that there are “No Recent Stories” related to Hemispherx.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 720 vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Hunter-Hopkins Center in Charlotte, N.C., where it will be used in the Expanded Access Program (”EAP”) known as “AMP-511”. The FDA authorized the AMP-511 protocol to treat ME/CFS patients in an effort to expand compassionate care in this dread disease which is estimated to disable more than 100,000 Americans. Hemispherx recently announced the expansion of the protocol, allowing new enrollees, who would not be eligible to participate in a future confirmatory trial.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States

    Herbert Cousins, SVP for Patient Relations, and Peter Rodino III, Director of Governmental Relations, spoke with patients and the clinician about the company’s progress in expanding its U.S. Treatment Protocol/Expanded Access Program for ME/CFS, known as AMP-511. Hemispherx announced the expansion of the program in June — allowing new enrollees for the first time in more than a year — after completing its first commercial-sized lot of its pipeline drug Ampligen, producing ~8,500 vials.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Issues Letter to Stockholders

    OCALA, Fla., Dec. 12, 2018 -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.